Literature DB >> 23843891

Towards an effective genital herpes vaccine: past lessons and future prospects.

William P Halford1.   

Abstract

Year:  2007        PMID： 23843891      PMCID： PMC3704169          DOI： 10.2217/17460794.2.1.1

Source DB:  PubMed          Journal:  Future Virol        ISSN： 1746-0794            Impact factor:   1.831


× No keyword cloud information.
  38 in total

1.  Genital herpes vaccine shows limited promise.

Authors:  J Stephenson
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

2.  Herpes simplex virus ICP0 and ICP34.5 counteract distinct interferon-induced barriers to virus replication.

Authors:  Karen L Mossman; James R Smiley
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 3.  The host response to herpes simplex virus infection.

Authors:  Gabriele Pollara; David R Katz; Benjamin M Chain
Journal:  Curr Opin Infect Dis       Date:  2004-06       Impact factor: 4.915

4.  The immediate-early protein, ICP0, is essential for the resistance of herpes simplex virus to interferon-alpha/beta.

Authors:  Peter Härle; Bruno Sainz; Daniel J J Carr; William P Halford
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

Review 5.  The Holy Grail: immune control of human herpes simplex virus infection and disease.

Authors:  A L Cunningham; Z Mikloska
Journal:  Herpes       Date:  2001-03

6.  Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons.

Authors:  A Wald; J Zeh; S Selke; T Warren; A J Ryncarz; R Ashley; J N Krieger; L Corey
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

7.  In vivo immune evasion mediated by the herpes simplex virus type 1 immunoglobulin G Fc receptor.

Authors:  T Nagashunmugam; J Lubinski; L Wang; L T Goldstein; B S Weeks; P Sundaresan; E H Kang; G Dubin; H M Friedman
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

Review 8.  Progress in the development of an HIV vaccine.

Authors:  Edmund C Tramont; Margaret I Johnston
Journal:  Expert Opin Emerg Drugs       Date:  2003-05       Impact factor: 4.191

Review 9.  Epidemiology of genital herpes.

Authors:  G R Kinghorn
Journal:  J Int Med Res       Date:  1994       Impact factor: 1.671

10.  Inhibition of MHC class I is a virulence factor in herpes simplex virus infection of mice.

Authors:  Mark T Orr; Kurt H Edelmann; Jeffrey Vieira; Lawrence Corey; David H Raulet; Christopher B Wilson
Journal:  PLoS Pathog       Date:  2005-09-30       Impact factor: 6.823
View more
  2 in total

1.  A live-attenuated HSV-2 ICP0 virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine.

Authors:  William P Halford; Ringo Püschel; Edward Gershburg; Andrew Wilber; Svetlana Gershburg; Brandon Rakowski
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

2.  Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.

Authors:  William P Halford; Ringo Püschel; Brandon Rakowski
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.